Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
Open accessAbstract
Immune checkpoint inhibitors (ICIs) with nivolumab and pembrolizumab are promising agents for advanced hepatocellular carcinoma (HCC) but lack of effective biomarkers. We aimed to investigate the potential predictors of response and factors associated with overall survival (OS) for ICI treatment in unresectable HCC patients. Ninety-five patients who received nivolumab or pembrolizumab for unresectable HCC were enrolled for analyses. Radiologic evaluation was based on RECIST v1.1. Factors associated with outcomes were analyzed. Of 90 patients with evaluable images, the objective response rate (ORR) was 24.4%. Patients at Child–Pugh A or received combination treatment had higher ORR. Early alpha-fetoprotein (AFP) >10% reduction (within 4 weeks) was the only independent predictor of best objective response (odds ratio: 7.259, p = 0.001). For patients with baseline AFP ≥10 ng/mL, significantly higher ORR (63.6% vs. 10.2%, p < 0.001) and disease control rate (81.8% vs. 14.3%, p < 0.001) were observed in those with early AFP reduction than those without. In addition, early AFP reduction and albumin-bilirubin (ALBI) grade or Child–Pugh class were independent factors associated with OS in different models. In conclusion, a 10-10 rule of early AFP response can predict objective response and survival to ICI treatment in unresectable HCC. ALBI grade and Child–Pugh class determines survival by ICI treatment.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · see citing works
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656 · see citing works
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406 · see citing works
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974 · see citing works
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · see citing works
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,606 · see citing works
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280 · see citing works
AASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2017) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,072 · see citing works
Johnson, P. J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M. J., Reeves, H. L., O’Beirne, J. P., Fox, R., Skowrońska, A., Palmer, D. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9151 · Cited by 2,799 · see citing works
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479 · see citing works
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784 · see citing works
Caldéraro, J., Rousseau, B., Amaddeo, G., Mercey-Ressejac, M., Charpy, C., Costentin, C. E., Luciani, A., Zafrani, E., Laurent, A., Azoulay, D., et al. (2016) · Hepatology · doi:10.1002/hep.28710 · Cited by 438 · see citing works
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
Yau, T. C. C., Hsu, C., Kim, T., Choo, S.-P., Kang, Y., Hou, M., Numata, K., Yeo, W., Chopra, A., Ikeda, M., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.014 · Cited by 264 · see citing works
Self-citationReig, M., Rimola, J., Torres, F., Darnell, A., de Lope, C. R., Forner, A., Llarch, N., Ríos, J., Ayuso, C., & Bruix, J. (2013) · Hepatology · doi:10.1002/hep.26586 · Cited by 257 · see citing works
Yau, T. C. C., Kang, Y., Kim, T., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M., Matilla, A. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4012 · Cited by 229 · see citing works
Self-citationFinn, R. S., Ryoo, B., Merle, P., Kudo, M., Bouattour, M., Lim, H.-Y., Breder, V. V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4004 · Cited by 204 · see citing works
Self-citationLiu, P., Hsu, C., Hsia, C., Lee, Y.-H., Chiou, Y., Huang, Y., Lee, F., Lin, H., Hou, M., & Huo, T. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13608 · Cited by 176 · see citing works
Self-citationShao, Y., Lin, Z., Hsu, C., Shen, Y., Hsu, C.-H., & Cheng, A. (2010) · Cancer · doi:10.1002/cncr.25257 · Cited by 172 · see citing works
Nivolumab for the treatment of hepatocellular carcinoma
Finkelmeier, F., Waidmann, O., & Trojan, J. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1535315 · Cited by 168 · see citing works
Khunger, M., Hernández, A. V., Pasupuleti, V., Rakshit, S., Pennell, N. A., Stevenson, J. P., Mukhopadhyay, S., Schalper, K. A., & Velcheti, V. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00030 · Cited by 155 · see citing works
Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
Kudo, M. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i7.789 · Cited by 143 · see citing works
Iavarone, M. A., Cabibbo, G., Biolato, M., Corte, C. D., Maida, M. F., Barbàra, M., Basso, M., Vavassori, S., Craxı̀, A., Grieco, A., et al. (2015) · Hepatology · doi:10.1002/hep.27729 · Cited by 130 · see citing works
Scheiner, B., Kirstein, M. M., Hucke, F., Finkelmeier, F., Schulze, K., von Felden, J., Koch, S., Schwabl, P., Hinrichs, J. B., Waneck, F., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15245 · Cited by 128 · see citing works
Ikeda, M., Sung, M. W., Kudo, M., Kobayashi, M., Baron, A. D., Finn, R. S., Kaneko, S., Zhu, A. X., Kubota, T., Kraljevic, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4076 · Cited by 125 · see citing works
Stein, S., Pishvaian, M. J., Lee, M. S., Lee, K.-H., Hernandez, S., Kwan, A., Liu, B., Grossman, W., Iizuka, K., & Ryoo, B. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4074 · Cited by 111 · see citing works
Cabibbo, G., Petta, S., Barbara, M., Attardo, S., Bucci, L., Farinati, F., Giannini, E. G., Negrini, G., Ciccarese, F., Rapaccini, G. L., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.033 · Cited by 110 · see citing works
Mehta, N. J., Dodge, J. L., Roberts, J. P., Hirose, R., & Yao, F. Y. (2018) · Hepatology · doi:10.1002/hep.30413 · Cited by 109 · see citing works
Shao, Y., Liu, T., Hsu, C., Lu, L., Shen, Y., Lin, Z., Cheng, A., & Hsu, C. (2019) · Liver International · doi:10.1111/liv.14210 · Cited by 107 · see citing works
Kambhampati, S., Bauer, K., Bracci, P. M., Keenan, B. P., Behr, S. C., Gordan, J. D., & Kelley, R. K. (2019) · Cancer · doi:10.1002/cncr.32206 · Cited by 104 · see citing works
Kudo, M., Matilla, A. M., Santoro, A., Melero, I., Gracián, A. C., Acosta-Rivera, M., Choo, S. P., El-Khoueiry, A. B., Kuromatsu, R., El‐Rayes, B. F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.327 · Cited by 98 · see citing works
Memon, K., Kulik, L., Lewandowski, R. J., Wang, E., Ryu, R. K., Riaz, A., Nikolaidis, P., Miller, F. H., Yaghmai, V., Baker, T., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.11.020 · Cited by 95 · see citing works
Finkelmeier, F., Czauderna, C., Perkhofer, L., Ettrich, T. J., Trojan, J., Weinmann, A., Marquardt, J. U., Vermehren, J., & Waidmann, O. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2780-8 · Cited by 44 · see citing works
Pinato, D. J., Yen, C., Bettinger, D., Ramaswami, R., Arizumi, T., Ward, C. E., Pirisi, M., Burlone, M. E., Thimme, R., Kudo, M., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13904 · Cited by 44 · see citing works
Lee, P., Chen, Y., Chao, Y., Huo, T., Li, C., Su, C., Lee, M., Hou, M., Lee, F., Lin, H., et al. (2017) · Liver International · doi:10.1111/liv.13527 · Cited by 44 · see citing works
Self-citationJung, J., Yoon, S. M., Han, S., Shim, J. H., Kim, K. M., Lim, Y., Lee, H. C., Kim, S. Y., Park, J., & Kim, J. H. (2015) · BMC Cancer · doi:10.1186/s12885-015-2017-z · Cited by 17 · see citing works
Meyer, T., Melero, I., Yau, T., Hsu, C., Kudo, M., Choo, S. P., Trojan, J., Welling, T. H., Kang, Y.-K., Yeo, W., et al. (2018) · Journal of Hepatology · doi:10.1016/s0168-8278(18)30249-6 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227 · see citing works
Demirtaş, C. Ö., D’Alessio, A., Rimassa, L., Sharma, R., & Pinato, D. J. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100347 · Cited by 230 · see citing works
Lee, P.-C., Wu, C.-J., Hung, Y.-W., Lee, C. J., Chi, C.-T., Lee, I.-C., Yu-Lun, K., Chou, S.-H., Luo, J.-C., Hou, M.-C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004779 · Cited by 217 · see citing works
Self-citationShao, Y., Wang, S.-Y., Lin, S., Chen, K.-Y., Tseng, J., Ho, M., Lee, R., Liang, P., Liao, L., Huang, K., et al. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.10.031 · Cited by 114 · see citing works
Self-citationProgress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
Lei, Y., Li, X., Huang, Q., Zheng, X., & Liu, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.617335 · Cited by 91 · see citing works
Lee, P., Chao, Y., Chen, M., Lan, K., Lee, I., Hou, M., & Huang, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001072 · Cited by 89 · see citing works
Self-citationImmune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma
Xie, E., Yeo, Y. H., Scheiner, B., Zhang, Y., Hiraoka, A., Tantai, X., Fessas, P., de Castro, T., D’Alessio, A., Fulgenzi, C. A. M., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.3284 · Cited by 87 · see citing works
An, Y., Wu, Z., Wang, N., Yang, Z., Li, Y., Xu, B., & Sun, M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02404-x · Cited by 83 · see citing works
Pinato, D. J., Kaneko, T., Saeed, A., Pressiani, T., Kaseb, A. O., Wang, Y., Szafron, D., Jun, T. W., Dharmapuri, S., Naqash, A. R., et al. (2020) · Cancers · doi:10.3390/cancers12071862 · Cited by 77 · see citing works
Self-citationImmunotherapy for hepatocellular carcinoma: Recent advances and future targets
Yu, S. J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108387 · Cited by 70 · see citing works
Zhang, L., Feng, J., Kuang, T., Chai, D., Qiu, Z., Deng, W., Dong, K., Zhao, K., & Wang, W. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110019 · Cited by 65 · see citing works
Fessas, P., Kaseb, A. O., Wang, Y., Saeed, A., Szafron, D., Jun, T. W., Dharmapuri, S., Naqash, A. R., Muzaffar, M., Navaid, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001033 · Cited by 60 · see citing works
Self-citationChoi, W., Lee, D., Shim, J. H., Kim, K. M., Lim, Y., Lee, H. C., Yoo, C., Park, S. R., Ryu, M., Ryoo, B., et al. (2020) · Cancers · doi:10.3390/cancers12071968 · Cited by 59 · see citing works
Recent advances in immunotherapy for hepatocellular carcinoma
Khan, A. A., Liu, Z., & Xu, X. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.06.010 · Cited by 56 · see citing works
Hayakawa, Y., Tsuchiya, K., Kurosaki, M., Yasui, Y., Kaneko, S., Tanaka, Y., Ishido, S., Inada, K., Kirino, S., Yamashita, K., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01185-4 · Cited by 55 · see citing works
Wu, C.-J., Lee, P., Hung, Y., Lee, C.-J., Chi, C., Lee, I., Hou, M., & Huang, Y. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03185-6 · Cited by 42 · see citing works
Self-citationMon, H.-C., Lee, P., Hung, Y.-P., Hung, Y., Wu, C.-J., Lee, C.-J., Chi, C., Lee, I., Hou, M., & Huang, Y. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.07.018 · Cited by 42 · see citing works
Self-citationAtezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
Cheon, J., Kim, H., Kim, H. S., Kim, C. G., Kim, I. H., Kang, B., Kim, C., Jung, S., Ha, Y., & Chon, H. J. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148541 · Cited by 36 · see citing works
Hung, H., Lee, J., Wang, Y., Cheng, C., Wu, T., Lee, C., Wu, T.-J., Chou, H., Chan, K., & Lee, W. (2021) · Cancers · doi:10.3390/cancers13071607 · Cited by 36 · see citing works
Self-citationSung, P. S., Jang, J. W., Lee, J., Lee, S. K., Lee, H. L., Yang, H., Nam, H. C., Lee, S. W., Bae, S. H., Choi, J. Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01043 · Cited by 33 · see citing works
Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
He, Y., Lu, M., Che, J., Chu, Q., Zhang, P., & Chen, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.716844 · Cited by 33 · see citing works
Kim, H. I., Lim, J., & Shim, J. H. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03727-y · Cited by 32 · see citing works
Reappraisal of the Role of Alkaline Phosphatase in Hepatocellular Carcinoma
Huang, C.-W., Wu, T., Hsu, H.-Y., Pan, K., Lee, C., Chong, S.-W., Huang, S.-F., Lin, S., Yu, M., & Chen, S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12040518 · Cited by 30 · see citing works
Self-citationTeng, W., Lin, C., Lin, P.-T., Hsieh, Y., Ho, M.-M., Hsieh, C.-H., Lin, C., & Lin, S. (2022) · Journal of Hepatology · doi:10.1016/s0168-8278(22)01098-4 · Cited by 30 · see citing works
Yu, J., Li, M., Ren, B., Cheng, L., Wang, X., Ma, Z., Yong, W. P., Chen, X., Wang, L., & Goh, B. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1261575 · Cited by 29 · see citing works
Immunotherapy in older patients with hepatocellular carcinoma
Lyu, N., Yi, J., & Zhao, M. D. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.024 · Cited by 29 · see citing works
Tsai, H., Han, M., Lin, Y., Chang, T., Chen, C., Cheng, P., Chuang, C., Wu, I., Chen, P., Kang, J., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02845-9 · Cited by 27 · see citing works
Mishra, G., Majeed, A., Dev, A. T., Eslick, G. D., Pinato, D. J., Izumoto, H., Hiraoka, A., Huo, T., Liu, P., Johnson, P. J., et al. (2022) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-022-00832-0 · Cited by 27 · see citing works
Liu, B., Shang, X., Shi, J., Cui, G., Li, X., & Wang, N.-Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.807189 · Cited by 25 · see citing works
Pallozzi, M., Tommaso, N. D., Maccauro, V., Santopaolo, F., Gasbarrini, A., Ponziani, F. R., & Pompili, M. (2022) · Cancers · doi:10.3390/cancers14194631 · Cited by 26 · see citing works
Pan, H., Zhou, L., Cheng, Z., Zhang, J., Shen, N., Ma, H., Li, Y., Jin, R., Zhou, W., Wu, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53704-5 · Cited by 25 · see citing works
Chen, S., Huang, Y., Chen, M., Hung, Y., Lee, R., Shao, Y., & Chao, Y. (2022) · BMC Cancer · doi:10.1186/s12885-022-09173-4 · Cited by 24 · see citing works
Self-citationKwee, S. A., & Tiirikainen, M. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2020.124 · Cited by 24 · see citing works
Yau, T. C. C., Tai, D. W.-M., Chan, S. L., Huang, Y., Choo, S. P., Hsu, C., Cheung, T. T., Lin, S., Yong, W. P., Lee, J. J. X., et al. (2022) · Liver Cancer · doi:10.1159/000525582 · Cited by 23 · see citing works
Self-citationPsilopatis, I., Damaskos, C., Garmpi, A., Sarantis, P., Koustas, E., Antoniou, E., Dimitroulis, D., Kouraklis, G., Karamouzis, M. V., Vrettou, K., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032685 · Cited by 22 · see citing works
Radiation-induced liver disease in the era of SBRT: a review
de la Pinta, C. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1814744 · Cited by 22 · see citing works
Teng, W., Lin, C., Ho, M.-M., Lui, K., Wang, S., Hsu, C., & Lin, S. (2021) · PubMed Central · Cited by 22 · see citing works
Kawashima, A., Yamamoto, Y., Sato, M., Nakata, W., Kakuta, Y., Ishizuya, Y., Yamaguchi, Y., Yamamoto, A., Yoshida, T., Takayama, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00509-x · Cited by 23 · see citing works
Immunotherapy-Based Treatments of Hepatocellular Carcinoma: AJR Expert Panel Narrative Review
Cannella, R., Lewis, S. C., da Fonseca, L. G., Ronot, M., & Rimola, J. (2022) · American Journal of Roentgenology · doi:10.2214/ajr.22.27633 · Cited by 21 · see citing works
Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
Lee, C., Chan, S., & Chon, H. (2022) · Cancers · doi:10.3390/cancers14133213 · Cited by 19 · see citing works
Self-citationDing, H., Liu, J., Wang, C., & Su, Y. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01520-4 · Cited by 19 · see citing works
Zhu, H., Feng, J.-K., Xiang, Y., Wang, K., Zhou, L.-P., Liu, Z., Cheng, Y., Shi, J., Guo, W., & Cheng, S. (2023) · BMC Cancer · doi:10.1186/s12885-023-11003-0 · Cited by 18 · see citing works
Hsu, W., Chuang, P., Chen, C., Wang, H., Tsai, M.-H., Su, W., Chen, H., Yang, C., Lin, C., Huang, G., et al. (2020) · PubMed Central · Cited by 18 · see citing works
Hsu, W., Wang, H., Chen, C., Lai, H., Chuang, P., Tsai, M.-H., Su, W., Chen, H., Chu, C., Chou, J., et al. (2021) · PubMed Central · Cited by 18 · see citing works
Self-citationChi, C., Lee, I., Lee, R., Hung, Y., Su, C., Hou, M., Chao, Y., & Huang, Y. (2021) · Cancers · doi:10.3390/cancers13174325 · Cited by 17 · see citing works
Self-citationHan, C., Tian, B., Yan, L., Ding, Z., Liu, H., Mao, X., Tian, J.-C., Xue, J.-S., Tan, S., Dong, Z., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03390-x · Cited by 17 · see citing works
Zhou, X., Cao, J., Topatana, W., Xie, T., Chen, T., Hu, J., Li, S., Juengpanich, S., Lu, Z., Zhang, B., et al. (2023) · Immunotherapy · doi:10.2217/imt-2022-0168 · Cited by 17 · see citing works
Self-citationSuzuki, K., Yasui, Y., Tsuchiya, K., Matsumoto, H., Yamazaki, Y., Uchihara, N., Tanaka, Y., Miyamoto, H., Yamada‐Shimizu, M., Keitoku, T., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16532 · Cited by 17 · see citing works
Hiraoka, A., Tanizawa, Y., Huang, Y., Cai, Z., & Sakaguchi, S. (2021) · Drugs - Real World Outcomes · doi:10.1007/s40801-021-00245-8 · Cited by 17 · see citing works
Self-citationThe rapidly evolving landscape of HCC: Selecting the optimal systemic therapy
Zanuso, V., Rimassa, L., & Braconi, C. (2023) · Hepatology · doi:10.1097/hep.0000000000000572 · Cited by 15 · see citing works
Hwang, S. Y., Zavareh, M. S. R., Attia, A. M., Kaymen, E. A., Tran, N. H., Abou‐Alfa, G. K., Parikh, N. D., Singal, A. G., & Yang, J. D. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003546 · Cited by 15 · see citing works
Tian, B., Yan, L., Ding, Z., Liu, H., Han, C., Meng, G.-X., Xue, J.-S., Dong, Z., Yan, Y., Hong, J., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109519 · Cited by 15 · see citing works
Wang, X., Yang, X., Wang, J., Dong, C., Ding, J., Wu, M., Wang, Y., Ding, H., Zhang, H., Sang, X., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s401647 · Cited by 14 · see citing works
Hsu, P., Cheng, T., Chuang, S., Chang, W., Liang, P., Hsu, C., Wei, Y., Jang, T., Yeh, M., Huang, C., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4430 · Cited by 13 · see citing works
Self-citationThe immune landscape of hepatocellular carcinoma‑where we are? (Review)
Gryziak, M., Woźniak, K., Kraj, L., Róg, L., & Stec, R. (2022) · Oncology Letters · doi:10.3892/ol.2022.13530 · Cited by 14 · see citing works
Lu, L., Zheng, P., Pan, Y., Huang, S., Shao, E., Huang, Y., Wang, X., Chen, Y., Cuo, G., Yang, H., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02334-7 · Cited by 13 · see citing works
Self-citationPark, J. E., Jo, J., Youk, J., Kim, M., Yoon, S. H., Keam, B., Kim, T. M., & Kim, D. (2023) · Insights into Imaging · doi:10.1186/s13244-023-01532-4 · Cited by 13 · see citing works
Ji, Z., Li, J., Zhang, S., Jia, Y., Zhang, J., & Guo, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1480520 · Cited by 13 · see citing works
Hsu, W., Hsu, S.-C., Chen, T.-H., Lin, C., Lin, Y., Chang, Y., Wang, H., Liao, Y.-M., Lai, H., & Peng, C. (2022) · Cancers · doi:10.3390/cancers14205083 · Cited by 13 · see citing works
Kinami, T., Amioka, K., Kawaoka, T., Uchikawa, S., Yamasaki, S., Kosaka, M., Johira, Y., Yano, S., Naruto, K., Ando, Y., et al. (2023) · Cancers · doi:10.3390/cancers15082304 · Cited by 13 · see citing works
Tian, B., Yan, L., Ding, Z., Liu, H., Meng, G.-X., Xue, J.-S., Han, C., Dong, Z., Hong, J., Chen, Z., et al. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2156859 · Cited by 12 · see citing works
Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma
Zhang, D., Zhu, Y., Shen, Z., Ma, S., Liu, S., & Lu, Z. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.02.010 · Cited by 12 · see citing works
Peng, T., Wu, C., Chang, S.-Y., Chen, Y.-C., Wu, T., & Hsu, C. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109223 · Cited by 13 · see citing works
Tian, B., Yan, L., & Liang, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1695861 · Cited by 11 · see citing works
Lee, I., Chao, Y., Lee, P., Chen, S., Chi, C., Wu, C.-J., Wu, K., Hou, M., & Huang, Y. (2022) · Cancers · doi:10.3390/cancers14082014 · Cited by 11 · see citing works
Self-citationXu, H., Cao, D., Zheng, Y., Zhou, D., Chen, X., Lei, J.-J., Ge, W., & Xu, X. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108135 · Cited by 10 · see citing works
Cammarota, A., Zanuso, V., Pressiani, T., Personeni, N., & Rimassa, L. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s268293 · Cited by 10 · see citing works
Liu, S., Li, Z., Lin, J., Ke, L., & Hua, Y. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70427 · Cited by 9 · see citing works
Cerrito, L., Ainora, M. E., Mosoni, C., Borriello, R., Gasbarrini, A., & Zocco, M. A. (2022) · Cancers · doi:10.3390/cancers14194647 · Cited by 9 · see citing works
Liu, Y., Pan, J., Gao, F., Xu, W., Li, H., & Qi, X. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02371-3 · Cited by 12 · see citing works
Ueno, M., Kosaka, H., Iida, H., Ida, Y., Aoi, K., Mori, H., Miyamoto, A., Nishida, Y., Hayami, S., Kawai, M., et al. (2023) · Oncology · doi:10.1159/000531317 · Cited by 9 · see citing works
Chen, S., Ho, H., Liu, C., Hung, Y., Chiang, N., Chen, M., Chao, Y., & Yang, M.-H. (2025) · BMC Cancer · doi:10.1186/s12885-025-13568-4 · Cited by 9 · see citing works
Self-citationHe, P., Wan, H., Wan, J., Jiang, H., Yu, Y., Xie, K., & Wu, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1015527 · Cited by 9 · see citing works
Kournoutas, I. A., Marell, P. S., Gile, J. J., Peersen, A. F., Shah, P., VanDommelen, K., Kamath, S. D., Gupta, G., Akce, M., Yang, J. D., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf286 · Cited by 8 · see citing works
Cheng, K.-L., Cheng, Y., Chan, C., & Wang, C. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-07984-4 · Cited by 8 · see citing works
Hsu, Y.-C., Lin, P., Teng, W., Hsieh, Y., Chen, W., Su, C., Wang, C., Chai, P., Lin, C., Lin, C.-Y., et al. (2024) · Cancers · doi:10.3390/cancers16203458 · Cited by 8 · see citing works
Kuo, H., Han, M., Liao, C., Lin, Y., Wang, C.-T., Chen, S., Chang, T., Chen, P., Lin, S., Chen, C., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112263 · Cited by 7 · see citing works
Self-citationIshizuya, Y., Kawashima, A., Horibe, Y., Yamamoto, A., Tani, M., Yoshimura, A., Liu, Y., Nesrine, S., Oka, T., Okuda, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-86212-7 · Cited by 6 · see citing works
Zou, H., Lei, Q., Yan, X., Lai, Y., Ung, C. O. L., & Hu, H. (2022) · Cancers · doi:10.3390/cancers15010260 · Cited by 6 · see citing works
Chan, K., Lai, Y., Hung, H., Lee, J., Cheng, C., Wang, Y., Wu, T., Lee, C., Wu, T.-J., Chou, H., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s393964 · Cited by 6 · see citing works
Self-citationZeng, Y., Gu, J., He, W., & Luo, J. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251387501 · Cited by 5 · see citing works
Zhang, Y., Shen, H., Zheng, R., Sun, Y., Xie, X., Lu, M., Liu, B., & Huang, G. (2023) · Cancers · doi:10.3390/cancers15215131 · Cited by 5 · see citing works
Cowzer, D., Chou, J. F., Walch, H. S., Keane, F., Khalil, D. N., Shia, J., Do, R. K. G., Yarmohammadi, H., Erinjeri, J. P., Dika, I. E., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae110 · Cited by 5 · see citing works
Swaroop, S., Biswas, S., Mehta, S., Aggarwal, A., Arora, U., Agarwal, S., Chavan, A., Nayak, B., & Shalimar, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14031034 · Cited by 5 · see citing works
Hsu, W., Lai, H., Chen, C., Wang, H., Chuang, P., Tsai, M.-H., Chen, S., Chu, C., Su, W., Chou, J., et al. (2023) · PubMed Central · Cited by 5 · see citing works
Self-citationJeng, L., Wang, J. C. K., & Teng, C. (2023) · Journal of Cancer · doi:10.7150/jca.90128 · Cited by 5 · see citing works
Huang, K.-W., Lee, P., Chao, Y., Su, C., Lee, I., Lan, K., Chu, C., Hung, Y., Chen, S., Hou, M., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221099401 · Cited by 4 · see citing works
Self-citationLee, S., Yang, S., & Lee, T. (2024) · Gastroenterology Research · doi:10.14740/gr1684 · Cited by 4 · see citing works
Ding, X., Zhang, K., & Xu, M. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.21.04282-8 · Cited by 4 · see citing works
Lee, P., Wu, C.-J., Lee, I., Lee, C.-J., Hou, M., & Huang, Y. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101491 · Cited by 3 · see citing works
Self-citationRajappa, S. J., Rau, K., Dattatreya, P. S., Ramaswamy, A., Fernandes, P., Pruthi, A., Cheng, R., Lukanowski, M., & Huang, Y. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i6.1074 · Cited by 3 · see citing works
Self-citationColloca, G. A., & Venturino, A. (2024) · Cancer · doi:10.1002/cncr.35199 · Cited by 3 · see citing works
Tian, J., Pan, S., Wang, Y., Yu, Y., Wang, S., Shen, Y., Yang, L., Liu, X., Qiu, Q., Luan, J., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12122769 · Cited by 2 · see citing works
Wonglhow, J., Sunpaweravong, P., Sathitruangsak, C., & Dechaphunkul, A. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14040403 · Cited by 2 · see citing works
Immunotherapy for hepatocellular carcinoma: The challenge of biomarker studies
Lee, I. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000458 · Cited by 2 · see citing works
Self-citationShan, X., Zhang, M., Lin, H., Zhu, M., & Li, M. (2021) · Trends in Oncology · doi:10.37155/2717-5278-2021-03-02-1 · Cited by 1 · see citing works
Right inguinal metastasis from hepatocellular carcinoma
Fu, C., Lei, H.-J., Wang, L., Wei, C., Su, C., Hou, M., Huang, Y., & Lee, P. (2021) · Advances in digestive medicine · doi:10.1002/aid2.13277 · Cited by 1 · see citing works
Self-citationGray, S., Lamarca, Á., McNamara, M. G., Edeline, J., Hanley, K. P., Valle, J. W., & Hubner, R. A. (2022) · Liver Cancer International · doi:10.1002/lci2.62 · Cited by 1 · see citing works
Lin, P.-T., Teng, W., Chen, W.-T., Su, C., Hsieh, Y., Lin, C., Lin, C., & Lin, S. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06381-w
Ding, H., Liu, J., Wang, C., & Su, Y. (2020) · Figshare · doi:10.6084/m9.figshare.12900428
- Authors
- Lee, P.-C., Chao, Y., Chen, M.-H., Lan, K.-H., Lee, C.-J., Lee, I.-C., Chen, S.-C., Hou, M.-C., & Huang, Y.-H.
- Affiliations
- Taipei Veterans General Hospital (TW)
- Corresponding author
- Chao, Yee
- Huang, Yi-Hsiang
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-01-11
- Volume
- 12
- Issue
- 1
- Pages
- 182
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC7017111
- OpenAlex
- W2999675465
- Cited by
- 105
- References
- 42
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 10 · 2023: 21 · 2022: 27 · 2021: 20 · 2020: 12
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Ministry of Science and Technology, Taiwan (MOST108-2628-B075-006, MOST 108-)
- Taipei Veterans General Hospital (V109C‐048)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- hepatocellular carcinoma, immune checkpoint inhibitors, nivolumab, pembrolizumab, predictive biomarkers, alpha-fetoprotein, objective response rate, overall survival, albumin-bilirubin grade, Child-Pugh score, combination therapy, RECIST 1.1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
